Stocks · Health care · Biological Products, (No Diagnostic Substances)

LENZ Therapeutics, Inc.

LENZ Clue Score42

United States Fiscal year ends December CIK 0001815776 Results filed 28 Oct 2026

Add to watchlist

By person

7 insiders · 3 transactions

0.3×

Evert Schimmelpennink holds only 0.3 times base salary in stock. $259.69K of shares against $690.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Evert Schimmelpennink last reported holding, valued at $3.36, the price Common Stock was last bought or sold at on the open market here, on 29 Oct 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Ra Capital Management, L.p. entity

10% owner

—

$9.13M (3)

−$9.13M

57,559

0.1832%

$193.40K

−97.9%

Versant Venture Capital VI, L.P. entity

10% owner

—

1,814,726

5.78%

$6.10M

−51.0%

Evert B. Schimmelpennink

President, CEO and Secretary

—

77,289

0.2460%

$259.69K

+71.8%

Daniel R. Chevallard

Chief Financial Officer

—

12,886

0.0410%

$43.30K

+304.2%

James W McCollum

Director

—

10,500

0.0334%

$35.28K

—

Jeffrey P. George

Director

—

5,592

0.0178%

$18.79K

—

Shawn Olsson

Chief Commercial Officer

—

4,733

0.0151%

$15.90K

—

LENZ Therapeutics, Inc.

What the insiders did Net selling

By person